Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma

Kazuaki Nakanishi, Michiie Sakamoto, Susumy Yamasaki, Satoru Todo, Setsuo Hirohashi

Research output: Contribution to journalArticle

176 Citations (Scopus)

Abstract

BACKGROUND. Patients with hepatocellular carcinoma (HCC) who showed early massive disease recurrence due to hematogenous intrahepatic metastasis after curative resection had a poor prognosis. The authors previously reported that Akt phosphorylation was correlated with hematogenous intrahepatic metastasis, using HCC cell lines. METHODS. The authors analyzed clinicopathologic features and the status of selected biologic markers, including phosphorylated Akt, to identify risk factors for early disease recurrence and poor prognosis in HCC. In the current series, 49 postoperative patients developed intrahepatic disease recurrence within 6 months (Group 1) and 86 patients remained disease recurrence free > 3 years after resection (Group 2). Group 1 was further divided into 2 subgroups: 19 patients who died of disease recurrence within a year after resection (Group 1A) and 27 patients who survived > 1 year (Group 1B). RESULTS. Using univariate analysis, the risk factors for early disease recurrence were tumor size, macroscopic classification, tumor differentiation, microscopic capsule infiltration, microscopic portal vein (MPV) invasion, microscopic intrahepatic metastasis (MIM), and positive immunostaining for phosphorylated Akt, Ki-67, and p53 (P < 0.05). The risk factors for poor prognosis were the number of intrahepatic metastases, tumor differentiation, and positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). Multivariate analysis revealed that the risk factors for early disease recurrence were MPV invasion, MIM, and positive immunostaining for phosphorylated Akt, and that the risk factors for poor prognosis were positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). CONCLUSIONS. The current clinical study showed the critical involvement of Akt phosphorylation in the aggressiveness of HCC. The potential benefits of surgery should be assessed carefully in patients with any of these risk factors.

Original languageEnglish
Pages (from-to)307-312
Number of pages6
JournalCancer
Volume103
Issue number2
DOIs
Publication statusPublished - 2005 Jan 15

Fingerprint

Hepatocellular Carcinoma
Phosphorylation
Recurrence
Neoplasm Metastasis
Portal Vein
Neoplasms
Capsules
Multivariate Analysis
Biomarkers
Cell Line

Keywords

  • Early disease recurrence
  • Hepatocellular carcinoma
  • Immunostaining
  • Phosphorylated Akt
  • Poor prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. / Nakanishi, Kazuaki; Sakamoto, Michiie; Yamasaki, Susumy; Todo, Satoru; Hirohashi, Setsuo.

In: Cancer, Vol. 103, No. 2, 15.01.2005, p. 307-312.

Research output: Contribution to journalArticle

Nakanishi, Kazuaki ; Sakamoto, Michiie ; Yamasaki, Susumy ; Todo, Satoru ; Hirohashi, Setsuo. / Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. In: Cancer. 2005 ; Vol. 103, No. 2. pp. 307-312.
@article{bf386143b573499aba771f1ebe2dfc6e,
title = "Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma",
abstract = "BACKGROUND. Patients with hepatocellular carcinoma (HCC) who showed early massive disease recurrence due to hematogenous intrahepatic metastasis after curative resection had a poor prognosis. The authors previously reported that Akt phosphorylation was correlated with hematogenous intrahepatic metastasis, using HCC cell lines. METHODS. The authors analyzed clinicopathologic features and the status of selected biologic markers, including phosphorylated Akt, to identify risk factors for early disease recurrence and poor prognosis in HCC. In the current series, 49 postoperative patients developed intrahepatic disease recurrence within 6 months (Group 1) and 86 patients remained disease recurrence free > 3 years after resection (Group 2). Group 1 was further divided into 2 subgroups: 19 patients who died of disease recurrence within a year after resection (Group 1A) and 27 patients who survived > 1 year (Group 1B). RESULTS. Using univariate analysis, the risk factors for early disease recurrence were tumor size, macroscopic classification, tumor differentiation, microscopic capsule infiltration, microscopic portal vein (MPV) invasion, microscopic intrahepatic metastasis (MIM), and positive immunostaining for phosphorylated Akt, Ki-67, and p53 (P < 0.05). The risk factors for poor prognosis were the number of intrahepatic metastases, tumor differentiation, and positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). Multivariate analysis revealed that the risk factors for early disease recurrence were MPV invasion, MIM, and positive immunostaining for phosphorylated Akt, and that the risk factors for poor prognosis were positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). CONCLUSIONS. The current clinical study showed the critical involvement of Akt phosphorylation in the aggressiveness of HCC. The potential benefits of surgery should be assessed carefully in patients with any of these risk factors.",
keywords = "Early disease recurrence, Hepatocellular carcinoma, Immunostaining, Phosphorylated Akt, Poor prognosis",
author = "Kazuaki Nakanishi and Michiie Sakamoto and Susumy Yamasaki and Satoru Todo and Setsuo Hirohashi",
year = "2005",
month = "1",
day = "15",
doi = "10.1002/cncr.20774",
language = "English",
volume = "103",
pages = "307--312",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma

AU - Nakanishi, Kazuaki

AU - Sakamoto, Michiie

AU - Yamasaki, Susumy

AU - Todo, Satoru

AU - Hirohashi, Setsuo

PY - 2005/1/15

Y1 - 2005/1/15

N2 - BACKGROUND. Patients with hepatocellular carcinoma (HCC) who showed early massive disease recurrence due to hematogenous intrahepatic metastasis after curative resection had a poor prognosis. The authors previously reported that Akt phosphorylation was correlated with hematogenous intrahepatic metastasis, using HCC cell lines. METHODS. The authors analyzed clinicopathologic features and the status of selected biologic markers, including phosphorylated Akt, to identify risk factors for early disease recurrence and poor prognosis in HCC. In the current series, 49 postoperative patients developed intrahepatic disease recurrence within 6 months (Group 1) and 86 patients remained disease recurrence free > 3 years after resection (Group 2). Group 1 was further divided into 2 subgroups: 19 patients who died of disease recurrence within a year after resection (Group 1A) and 27 patients who survived > 1 year (Group 1B). RESULTS. Using univariate analysis, the risk factors for early disease recurrence were tumor size, macroscopic classification, tumor differentiation, microscopic capsule infiltration, microscopic portal vein (MPV) invasion, microscopic intrahepatic metastasis (MIM), and positive immunostaining for phosphorylated Akt, Ki-67, and p53 (P < 0.05). The risk factors for poor prognosis were the number of intrahepatic metastases, tumor differentiation, and positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). Multivariate analysis revealed that the risk factors for early disease recurrence were MPV invasion, MIM, and positive immunostaining for phosphorylated Akt, and that the risk factors for poor prognosis were positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). CONCLUSIONS. The current clinical study showed the critical involvement of Akt phosphorylation in the aggressiveness of HCC. The potential benefits of surgery should be assessed carefully in patients with any of these risk factors.

AB - BACKGROUND. Patients with hepatocellular carcinoma (HCC) who showed early massive disease recurrence due to hematogenous intrahepatic metastasis after curative resection had a poor prognosis. The authors previously reported that Akt phosphorylation was correlated with hematogenous intrahepatic metastasis, using HCC cell lines. METHODS. The authors analyzed clinicopathologic features and the status of selected biologic markers, including phosphorylated Akt, to identify risk factors for early disease recurrence and poor prognosis in HCC. In the current series, 49 postoperative patients developed intrahepatic disease recurrence within 6 months (Group 1) and 86 patients remained disease recurrence free > 3 years after resection (Group 2). Group 1 was further divided into 2 subgroups: 19 patients who died of disease recurrence within a year after resection (Group 1A) and 27 patients who survived > 1 year (Group 1B). RESULTS. Using univariate analysis, the risk factors for early disease recurrence were tumor size, macroscopic classification, tumor differentiation, microscopic capsule infiltration, microscopic portal vein (MPV) invasion, microscopic intrahepatic metastasis (MIM), and positive immunostaining for phosphorylated Akt, Ki-67, and p53 (P < 0.05). The risk factors for poor prognosis were the number of intrahepatic metastases, tumor differentiation, and positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). Multivariate analysis revealed that the risk factors for early disease recurrence were MPV invasion, MIM, and positive immunostaining for phosphorylated Akt, and that the risk factors for poor prognosis were positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). CONCLUSIONS. The current clinical study showed the critical involvement of Akt phosphorylation in the aggressiveness of HCC. The potential benefits of surgery should be assessed carefully in patients with any of these risk factors.

KW - Early disease recurrence

KW - Hepatocellular carcinoma

KW - Immunostaining

KW - Phosphorylated Akt

KW - Poor prognosis

UR - http://www.scopus.com/inward/record.url?scp=12344289067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344289067&partnerID=8YFLogxK

U2 - 10.1002/cncr.20774

DO - 10.1002/cncr.20774

M3 - Article

VL - 103

SP - 307

EP - 312

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -